Compare Oatly Group AB - ADR (OTLY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Recursion Pharmaceuticals Inc — how do they compare? Oatly Group AB - ADR trades at $10.59 (market cap $330.93M), while Recursion Pharmaceuticals Inc trades at $4.26 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 6.5× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is more actively traded (68,708 versus 30,789,535). Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| OTLY | RXRX | |
|---|---|---|
Market Cap | $330.93M | $2.14B |
Volume | 68,708 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $6.79 |
52-Week Low | $8.03 | $2.84 |
Typical Hold Time | 18 Days | 23 Days |
Enterprise Value | $835.34M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oatly (OTLY) trades at $10.42, up 0.48% on the day, amid mixed technical signals and ongoing fundamental challenges. The stock shows a bearish moving average trend but bullish oscillators, with key support at $10. Revenue growth is steady, reaching $862.46M in 2025, yet profitability remains elusive with a net income margin of -13.81%. Recent Q2 2026 results beat expectations, and management raised full-year revenue guidance, driving positive sentiment from some analysts.
The outlook is cautiously optimistic, with a consensus price target of $12.28 suggesting 18% upside, but significant risks persist. High debt levels, negative cash flows, and intense competition in the plant-based food sector threaten near-term stability. Investors should weigh the potential for operational turnaround against persistent losses and leverage concerns before considering a position.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
